|
Medical Advocates Nevirapine (Viramune) |
|
|
Journal Main Page |
|
|
Last
Update:
December 11, 2008
|
| Tolerance Induction | |||||
|
Long-term safety and efficacy of nevirapine tolerance
induction. Messaad D, Reynes J, Fabre J, et al. Clin Exp Allergy. 2002 May;32(5):733-735. Abstract |
|
NVP-Based HAART and
Fluconazole
Cryptococcal Prophylaxis |
|
FULL-TEXT PDF ARTICLE Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a case-control study Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S BMC Infectious Diseases 2005, 5:67 Paper |
| Lipodystrophy Prevention | |||||
|
Switching to nevirapine decreases insulin levels but does not improve
subcutaneous a dipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. Domingo P, Matias-Guiu X, Pujol RM, et al. J Infect Dis 2001 Nov 1;184(9):1197-201 Abstract |
| Coronary Risk | |||||
|
in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. Clin Endocrinol Metab. 2003 Nov;88(11):5186-92 |
| Central Nervous System Benefits | |||||
|
Therapeutic effects of nonnucleoside reverse transcriptase
inhibitors on the central nervous system in HIV-1-infected patients. von Giesen HJ, Koller H, Theisen A, Arendt G. J Acquir Immune Defic Syndr 2002 Apr 1;29(4):363-7 Abstract |
|
Undetectable Viral Load |
||||||
|
-Infected Patients with Undetectable Virus Load. Abstract |
| Simplification Therapy |
|
nevirapine, efavirenz or abacavir. de Echaguen AO, Arnedo M, Xercavins M, et al AIDS. 2005 Sep 2;19(13):1385-1391. |
| Salvage Therapy | |||||
|
Nelfinavir plus nevirapine plus two nrtis as salvage therapy for
hiv-infected
patients receiving antiretroviral treatment. Perez-Molina JA, Perez Nr R, et al HIV Clin Trials 2001 Jan-Feb;2(1):1-5 Abstract
|
| Stopping NVP-Based Therapy | |||||
|
| Adherence and Dosing |
|
controlled study. Parienti JJ, Massari V, Reliquet V, et a AIDS. 2007 Oct;21(16):2217-2222. Abstract |
| HIV Pre-exposure Prophylaxis |
|
A phase I/II study of nevirapine for pre-exposure
prophylaxis of HIV-1 transmission
in uninfected subjects at high risk. Jackson JB, Barnett S, Piwowar-Manning E, et al. AIDS 2003 Mar 7;17(4):547-53 Abstract |
| HIV/TB Coinfection | |||||
Increasing
Nevirapine Dose Can Overcome Reduced Bioavailability Due to
Rifampicin |
|
|
|
|
|
|
Nevirapine Journal Data |